

1633/8
Docket No.: 14129-00001-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Carsten Hopf

Application No.: 10/570,909

Confirmation No.: 1220

Filed: March 29, 2006

Art Unit: 1633

For: TREATMENT OF NEURODEGENERATIVE
DISEASES

Examiner: Hill, Kevin Kai

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

08/17/2007 ATRINH 00000026 032775 10570909


The documents listed on the attached SB/08 are the documents cited in the International Search Report during the prosecution of international application no. PCT/EP2004/09771, which corresponds to the above referenced application. In accordance with 37 CFR 1.97(b)(2), Applicant hereby submits these documents for the Examiner's consideration.

Please note that a copy of WO 00/58473 listed on the attached SB/08 is enclosed with the pages associated with the sequences cited in the International Search Report. The total sequence listing, including the tables associated with the sequence listing, for WO 00/58473 is 5,510 pages. The total sequence listing can be provided at any time to the Examiner. If agreeable to the Examiner, we can provide the total sequence listing on CD.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. Moreover, Applicant understands the Examiner will make an independent evaluation of the cited documents.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 14129-00001-US from which the undersigned is authorized to draw.

Respectfully submitted,

By 
Hui-Ju Wu

Registration No.: 57,209
CONNOLLY BOVE LODGE & HUTZ LLP
1007 North Orange Street
P.O. Box 2207
Wilmington, Delaware 19899
(302) 658-9141
(302) 658-5614 (Fax)
Agent for Applicants

#558054



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/570,909


Attorney Docket No.: 14129-00001-US

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 14, 2007
Date


Signature

Deborah Israel

Typed or printed name of person signing Certificate

Registration Number, if applicable

(302) 658-9141
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement Transmittal (2 pgs)
Information Disclosure Statement (1 pg) w/7 references
Fee Transmittal (1 pg)
Postcard
Charge \$180.00 to Deposit Account 03-2775



PTO/SB/17 (07-07)

Approved for use through 06/30/2010. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|--|--|--------------------------|------------------------|
| FEE TRANSMITTAL For FY 2007 | | Complete if Known | |
| | | Application Number | 10/570,909-Conf. #1220 |
| | | Filing Date | March 29, 2006 |
| | | First Named Inventor | Carsten Hopf |
| | | Examiner Name | Hill, Kevin Kai |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 | | Art Unit | 1633 |
| TOTAL AMOUNT OF PAYMENT | | (\$) | 180.00 |
| | | Attorney Docket No. | 14129-00001-US |

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 03-2775 Deposit Account Name: Connolly Bove Lodge & Hutz LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

| Application Type | FILING FEES | | SEARCH FEES | | EXAMINATION FEES | | Fees Paid (\$) |
|------------------|-------------|-----------------------|-------------|-----------------------|------------------|-----------------------|----------------|
| | Fee (\$) | Small Entity Fee (\$) | Fee (\$) | Small Entity Fee (\$) | Fee (\$) | Small Entity Fee (\$) | |
| Utility | 300 | 150 | 500 | 250 | 200 | 100 | |
| Design | 200 | 100 | 100 | 50 | 130 | 65 | |
| Plant | 200 | 100 | 300 | 150 | 160 | 80 | |
| Reissue | 300 | 150 | 500 | 250 | 600 | 300 | |
| Provisional | 200 | 100 | 0 | 0 | 0 | 0 | |

2. EXCESS CLAIM FEES

| Fee Description | Fee (\$) | Small Entity Fee (\$) |
|--|----------|-----------------------|
| Each claim over 20 (including Reissues) | 50 | 25 |
| Each independent claim over 3 (including Reissues) | 200 | 100 |
| Multiple dependent claims | 360 | 180 |

Total Claims Extra Claims Fee (\$) Fee Paid (\$) Multiple Dependent Claims

_____ - 56 = _____ x _____ = _____ Fee (\$) Fee Paid (\$)

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims Extra Claims Fee (\$) Fee Paid (\$)

_____ - 3 = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)

_____ - 100 = _____ /50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

| | | | |
|---------------------|-----------|-----------------------------------|-----------------|
| SUBMITTED BY | | | |
| Signature | | Registration No. (Attorney/Agent) | 57,209 |
| Name (Print/Type) | Hui-Ju Wu | Telephone | (302) 658-9141 |
| | | Date | August 14, 2007 |



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

| | | | | | |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/570,909-Conf. #1220 |
| | | | | Filing Date | March 29, 2006 |
| | | | | First Named Inventor | Carsten Hopf |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | Hill, Kevin Kai |
| Sheet | 1 | of | 1 | Attorney Docket Number | 14129-00001-US |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------------------|---------------------------|--|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁴ |
| | | Country Code ³ | Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | BA | WO-00/53770 | | 09-14-2000 | Multigene Biotech GmbH | | |
| | BB | WO-00/58473 | | 10-05-2000 | Curagen Corporation | | |
| | BC | WO-01/49871 | | 07-12-2001 | Boehringer Ingelheim Pharma KG | | |
| | BD | WO-01/62897 | | 08-30-2001 | Vlaams Interuniversitair Instituut voor Biotechnologie VZW | | |
| | BE | WO-01/70993 | | 09-27-2001 | Scotia Holdings PLC | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CA | Cho, H. P., et al., "Cloning, Expression, and Nutritional Regulation of the Mammalian Δ -6 Desaturase", The Journal of Biological Chemistry, 1999, Vol. 274, No. 1, pp. 471-477. | |
| | CB | Hopf, C., et al., "Discovery of New Therapeutic Targets by Integrated Protein Pathway and Chemical Proteomic Analysis of APP Processing", Society for Neuroscience Abstract Viewer and Itinerary Planner, 2003, Abstract No. 406.5, presented in the 33 rd Annual Meeting of the Society of Neuroscience, New Orleans, LA, U.S.A., November 8-12, 2003. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

558053